The most common side effects of bedaquiline in studies were nausea, joint and chest pain, and headache. The drug also has ablack-box warning for increased risk of death andarrhythmias, as it may prolong the QT interval by blocking thehERG channel.[15] Everyone on bedaquiline should have monitoring with a baseline and repeatedECGs.[3]
There is considerable controversy over the approval for the drug, as one of the largest studies to date had more deaths in the group receiving bedaquiline that those receiving placebo.[16] Ten deaths occurred in the bedaquiline group out of 79, while two occurred in the placebo group, out of 81.[17] Of the 10 deaths on bedaquiline, one was due to a motor vehicle accident, five were judged as due to progression of the underlying tuberculosis and three were well after the person had stopped receiving bedaquiline.[16] There remains significant concern for the higher mortality in people treated with bedaquiline, leading to the recommendation to limit its use to situations where a four drug regimen cannot otherwise be constructed, limit use with other medications that prolong the QT interval, and the placement of a prominentblack box warning.[16][18]
Bedaquiline should not be co-administered with other drugs that are strong inducers or inhibitors ofCYP3A4, the liver enzyme responsible for oxidative metabolism of the drug.[3] Co-administration withrifampin, a strong CYP3A4 inducer, results in a 52% decrease in theAUC of the drug. This reduces the exposure of the body to the drug and decreases the antibacterial effect. Co-administration withketoconazole, a strong CYP3A4 inhibitor, results in a 22% increase in the AUC, and potentially an increase in the rate of adverse effects experienced.[3]
Bedaquiline blocks theproton pump forATP synthase of mycobacteria.[19] It is the first member of a class of drugs called thediarylquinolines.[19] Bedaquiline is bactericidal.[19] ATP production is required for cellular energy production and its loss leads inhibition of mycobacterial growth within hours of the addition of bedaquiline.[20] The onset of bedaquiline-induced mycobacterial cell death does not occur until several days after treatment, but nonetheless kills consistently thereafter.[20]
The specific part of ATP synthase affected by bedaquiline is subunit c which is encoded by the gene atpE. Mutations in atpE can lead to resistance. Mutations in drugefflux pumps have also been linked to resistance.[21]
Bedaquiline was described for the first time in 2004 at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting, after the drug had been in development for over seven years.[22] It was discovered by a team led byKoen Andries atJanssen Pharmaceutica.[23]
Bedaquiline was approved for medical use in the United States in 2012.[1]
It is manufactured byJohnson & Johnson (J&J), who soughtaccelerated approval of the drug, a type of temporary approval for diseases lacking other viable treatment options.[24] By gaining approval for a drug that treats a neglected disease, J&J is now able to request expedited FDA review of a future drug.[25]
When it was approved by the FDA in December 2012, it was the first new medicine for TB in more than 40 years.[26][27]
In 2016, the WHO came under criticism for recommending it as an essential medicine.[28]
The WHO TB program director has pointed out that Janssen will donate $30million worth (30,000 treatment courses) of bedaquiline over a four-year period.[29]
In 2023, a request to extend the patent on bedaquiline until 2027, was rejected by the Indian patent office.[30] The patent was supposed to expire in July 2023, but J&J'severgreening practices will not allow the distribution ofgenerics in several countries heavily afflicted by tuberculosis.[31]
In July 2023, the WHO's Stop TB program and Johnson & Johnson came to an agreement allowing for Stop TB Partnership's Global Drug Facility to produce generic bedaquiline for the majority of low and middle income countries.[32]
In July 2024, theIndian Patent Office’s rejectedJohnson & Johnson's application for a pediatric version of bedaquiline, paving the way for more affordablegeneric alternatives, potentially reducing treatment costs by 80% beyond the primarypatent’s expiration in July 2023.[33]
The cost for six months is approximatelyUS$900 in low-income countries, $3,000 in middle-income countries, and $30,000 in high-income countries.[34]
The public sector invested $455–747million in developing bedaquiline. This is thought to be 1.6x to 5.1x what the owner,Janssen Biotech, invested (estimated at $90–240million). If capitalized and risk-adjusted, these costs become $647–1,201million and $292–772million, respectively.[35]
In vitro experiments have indicated that bedaquiline may also target themitochondrial ATP synthase ofmalignant mammalian cells and reduce the rate ofmetastasis.[36]
Bedaquiline has been studied inphase IIb studies for the treatment of multidrug-resistant tuberculosis while phase III studies are currently underway.[18] It has been shown to improve cure rates of smear-positive multidrug-resistant tuberculosis, though with some concern for increased rates of death.[17]
^abcdefghi"Bedaquiline Fumarate". The American Society of Health-System Pharmacists.Archived from the original on 20 December 2016. Retrieved8 December 2016.
^World Health Organization (2023).The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization.hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
^Protopopova M, Bogatcheva E, Nikonenko B, Hundert S, Einck L, Nacy CA (May 2007). "In search of new cures for tuberculosis".Medicinal Chemistry.3 (3):301–16.doi:10.2174/157340607780620626.PMID17504204.
^World Health Organization (2015).The selection and use of essential medicines. Twentieth report of the WHO Expert Committee 2015 (including 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. pp. 26–30.hdl:10665/189763.ISBN9789241209946.ISSN0512-3054. WHO technical report series;994.
